PTHS
Pelthos Therapeutics·AMEX
--
--(--)
--
--(--)
PTHS fundamentals
During Q4 2025, Pelthos Therapeutics (PTHS) reported revenue of 9.39M, a YoY change of 0.00%. Net income was -21.66M, a YoY change of -1024.82%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 7.41M -- | 9.39M -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 7.41M -- | 9.39M -- | -- -- |
Cost of Revenue | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 2.32M -- | 1.67M -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 2.32M -- | 1.67M -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 5.09M -- | 7.72M -- | -- -- |
Operating Expenses | 184.26K -- | 209.97K -- | 287.85K -- | 296.65K -- | 518.84K +181.57% | 1.21M +478.57% | 914.58K +217.73% | 777.16K +161.97% | 1.29M +148.96% | 3.88M +219.29% | 1.93M +111.46% | 1.76M +126.99% | 2.05M +58.62% | 1.82M -52.98% | 1.83M -5.17% | 3.23M +83.12% | 20.45M +898.15% | 19.72M +981.14% | 45.24M -- |
Selling, General and Administrative Expenses | 135.41K -- | 260.09K -- | 65.29K -- | 162.76K -- | 143.23K +5.78% | 1.56M +497.93% | 477.63K +631.52% | 537.88K +230.47% | 1.24M +767.56% | 1.58M +1.89% | 1.47M +207.22% | 1.75M +225.56% | 1.63M +31.50% | 1.54M -2.88% | 1.64M +11.74% | 2.72M +55.08% | 18.53M +1034.21% | 21.12M +1272.32% | 44.01M -- |
Selling and Marketing Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 4.93M -- | -4.93M -- | -- -- |
General and Administrative Expenses | -- -- | 496.67K -- | -- -- | -- -- | -- -- | 1.10M +121.24% | -- -- | -- -- | 661.57K -- | 1.06M -3.37% | 787.56K -- | 1.21M -- | 803.00K +21.38% | -2.68M -352.57% | 1.09M +38.41% | 1.11M -8.25% | 1.32M +64.26% | -4.02M -49.85% | -499.87K -- |
Research and Development Expenses | 32.21K -- | 60.06K -- | 42.59K -- | 26.57K -- | 27.98K -13.14% | 294.58K +390.50% | 186.12K +336.97% | 49.95K +87.99% | 49.13K +75.59% | 2.29M +678.80% | 466.61K +150.71% | 12.96K -74.07% | 415.00K +744.66% | 285.00K -87.58% | 194.30K -58.36% | 514.81K +3873.86% | 145.00K -65.06% | 374.00K +31.23% | 1.23M -- |
Other Operating Expenses | 16.65K -- | -110.18K -- | 179.96K -- | 107.32K -- | 347.63K +1988.39% | -634.91K -476.27% | 250.84K +39.39% | 189.33K +76.41% | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 1.77M -- | -1.77M -- | -- -- |
Operating Income | -184.26K -- | -209.97K -- | -287.85K -- | -296.65K -- | -518.84K -181.57% | -1.21M -478.57% | -914.58K -217.73% | -777.16K -161.97% | -1.29M -148.96% | -3.88M -219.29% | -1.93M -111.46% | -1.76M -126.99% | -2.05M -58.62% | -1.82M +52.98% | -1.83M +5.17% | -3.23M -83.12% | -15.36M -649.73% | -12.00M -558.06% | -32.43M -- |
Non-Operating Income (Loss) | 0 -- | 0 -- | -22.61K -- | -37.40K -- | -37.81K -- | -42.61K -- | -51.98K -129.94% | -176.19K -371.08% | -130.01K -243.82% | -160.34K -276.27% | -628.35K -1108.87% | -7.53K +95.72% | 354.00K +372.30% | -102.00K +36.38% | -133.63K +78.73% | -218.52K -2800.78% | -1.34M -478.81% | -16.58M -16157.84% | -18.28M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -14.98M -- | -- -- |
Other Non-Operating Income (Loss) | 0 -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -285.00K -- | -- -- |
Net Interest Expense | 0 -- | 0 -- | 22.61K -- | 37.40K -- | 37.81K -- | 42.61K -- | 51.98K +129.94% | 176.19K +371.08% | 130.01K +243.82% | 160.34K +276.27% | 628.35K +1108.87% | 7.53K -95.72% | -354.00K -372.30% | 102.00K -36.38% | 133.63K -78.73% | 218.52K +2800.78% | 1.34M +478.81% | 1.31M +1188.24% | 3.01M -- |
Interest Expense | 0 -- | 0 -- | 22.61K -- | 37.40K -- | 37.81K -- | 42.61K -- | 51.98K +129.94% | 176.19K +371.08% | 130.01K +243.82% | 160.34K +276.27% | 628.35K +1108.87% | 11.06K -93.72% | 39.00K -70.00% | 108.00K -32.64% | 133.63K -78.73% | 218.52K +1875.73% | 1.35M +3351.28% | 1.31M +1116.67% | 3.01M -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.53K -- | 393.00K -- | 6.00K -- | -- -- | 0 -100.00% | 5.00K -98.73% | 0 -100.00% | -- -- |
Pretax Income From Continuing Operations | -184.26K -- | -209.97K -- | -310.45K -- | -334.06K -- | -556.65K -202.09% | -1.26M -498.87% | -966.56K -211.34% | -953.35K -185.39% | -1.42M -155.41% | -4.04M -221.22% | -2.56M -165.10% | -1.77M -85.83% | -1.70M -19.22% | -1.93M +52.32% | -1.97M +23.21% | -3.45M -94.68% | -16.70M -885.43% | -28.59M -1384.22% | -50.71M -- |
Income Tax Expense | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -465.00K -- | -6.92M -- | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -7.39M -- | -- -- |
Net Income | -184.26K -- | -209.97K -- | -310.45K -- | -334.06K -- | -556.65K -202.09% | -1.26M -498.87% | -966.56K -211.34% | -953.35K -185.39% | -1.42M -155.41% | -4.04M -221.22% | -2.56M -165.10% | -1.77M -85.83% | -1.70M -19.22% | -1.93M +52.32% | -1.97M +23.21% | -3.45M -94.68% | -16.24M -857.99% | -21.66M -1024.82% | -43.32M -- |
Net Income Attributable to Owners of the Company | -184.26K -- | -209.97K -- | -310.45K -- | -334.06K -- | -556.65K -202.09% | -1.26M -498.87% | -966.56K -211.34% | -953.35K -185.39% | -1.42M -155.41% | -4.04M -221.22% | -2.56M -165.10% | -1.77M -85.83% | -1.70M -19.22% | -1.93M +52.32% | -1.97M +23.21% | -3.45M -94.68% | -16.24M -857.99% | -21.66M -1024.82% | -43.32M -- |
Net Income Attributable to Common Stockholders | -184.26K -- | -209.97K -- | -310.45K -- | -334.06K -- | -556.65K -202.09% | -1.26M -498.87% | -966.56K -211.34% | -953.35K -185.39% | -1.42M -155.41% | -4.04M -221.22% | -2.56M -165.10% | -1.77M -85.83% | -1.70M -19.22% | -1.93M +52.32% | -1.97M +23.21% | -3.45M -94.68% | -16.24M -857.99% | -21.66M -1024.82% | -43.32M -- |
Other Comprehensive Income | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.70M -- | -1.93M -- | -- -- | -- -- | -16.24M -857.99% | -21.66M -1024.82% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.70M -- | -1.93M -- | -- -- | -- -- | -16.24M -857.99% | -21.66M -1024.82% | -- -- |
Basic EPS | -- -- | -- -- | -- -- | -- -- | -0.1 -- | -- -- | -0.87 -- | -0.95 -- | -1.44 -1340.00% | -- -- | -0.55 +36.78% | -3.07 -223.16% | -2.93 -103.47% | -0.32 -- | -0.32 +41.82% | -5.38 -75.24% | -5.3 -80.89% | -6.7 -1993.75% | -17.7 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.44 -- | -- -- | -0.55 -- | -3.07 -- | -2.93 -103.47% | -- -- | -0.32 +41.82% | -5.38 -75.24% | -5.3 -80.89% | -- -- | -- -- |
Diluted EPS | -- -- | -- -- | -- -- | -- -- | -0.1 -- | -- -- | -0.87 -- | -0.95 -- | -1.44 -1340.00% | -- -- | -0.55 +36.78% | -3.07 -223.16% | -2.93 -103.47% | -- -- | -0.32 +41.82% | -5.38 -75.24% | -5.3 -80.89% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.44 -- | -- -- | -0.55 -- | -3.07 -- | -2.93 -103.47% | -- -- | -0.32 +41.82% | -5.38 -75.24% | -5.3 -80.89% | -- -- | -- -- |
You can ask Aime
What were the key takeaways from Pelthos Therapeutics's earnings call?What is the revenue and EPS growth rate for Pelthos Therapeutics year over year?What is Pelthos Therapeutics's latest dividend and current dividend yield?What does Pelthos Therapeutics do and what are its main business segments?What factors drove the changes in Pelthos Therapeutics's revenue and profit?What is Pelthos Therapeutics's gross profit margin?What is the market's earnings forecast for Pelthos Therapeutics next quarter?Did Pelthos Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
